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As a home visit FNP, you see an 81 year old female with
a PMH of:
• Atrial fibrillation
• Myocardial infarction
• Rheumatoid arthritis (RA)
• Osteoarthritis
• Dementia with agitation
• B12 deficiency (corrected)
Felty s syndrome (FS)
Medications include:
• Amlodipine 5 mg daily
• Aricept 5 mg daily
• Buspirone 10 mg daily
• Digoxin 125 mcg daily
• Omeprazole 20 mg daily
• Seroquel 50 mg daily
• Toprol XL 50 mg daily
• Vitamin D 1000 units daily
• Xarelto 20 mg daily
ROS is negative except for some fatigue, occasional
palpitations when upset, nocturia, visual hallucinations
and insomnia.
Physical exam elicits an irregular HR, a II/VI systolic
murmur at the LLS border and RA deformities
(significant ulnar deviation involving both metacarpal
phalangeal joints and swan neck deformities).
You order initial blood work with results that include:
• WBC 1.7 (3.8-10.8 thousand/uL)
• MCV 77.0 (80-100 fL)
• MCH 24.8 (27-33 pg)
• RDW 18.0 (11-15%)
• Platelet count 120 (140-400 thousand/uL)
• Absolute neutrophils 153 (1500-7800 cells/uL)
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Incidence is difficult to estimate since a large proportion of
patients are asymptomatic
Affects only 1-3 % of RA patients (Woolston & Connelly, 2017)
Three times more common in females
Strong association between FS and HLA-DR4 genotype,
suggesting an important role for chronic inflammation in those
genetically predisposed (Kay, 2017)
Skin, pulmonary and mouth infections are more common with FS
Weight loss is prominent, along with an increased overall risk of
all cancers (Owlia et al., 2014)
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•

•
•

•

A repeat CBC confirms these results.
Are these results concerning with a history of FS?

Is characterized by a triad of symptoms: seropositive RA with
severe joint involvement, splenomegaly, and neutropenia (Owlia,
Newman & Akhtari (2014).
Was first described in 1924 by Augustus Roi Felty as a potentially
serious systemic condition complicating long standing RA.
Does not require the complete triad of symptoms for diagnosis,
but persistent neutropenia with an absolute neutrophil count <
1500/mm3 establishes the diagnosis (Kay, 2017).

Patients may present with anemia of chronic disease and
thrombocytopenia
Rheumatoid factor titers may be high, along with positive ANA,
anti-perinuclear antibodies and anti-keratin antibodies (neither
sensitive nor specific for diagnosis)
ESR is constantly elevated
Bone marrow aspiration and biopsy are recommended with initial
diagnosis to r/o other hematological and non-hematological
malignancies (Owlia et al., 2014).
Differential diagnoses may include: SLE, large granular
lymphocyte syndrome, other myeloproliferative or
lymphoproliferative disorders that cause splenomegaly and/or
neutropenia (Kay, 2017).

Treatment
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No definitive treatment for FS
Isolated neutropenia not an indication for treatment unless
granulocyte count < 1000/mm3
Constitutional symptoms, such as fever, warrant administration of
broad-spectrum antibiotics (Owlia et al., 2014).
Methotrexate and low dose granulocyte colony stimulating factor
(G-CSF) may be considered in FS patients with neutropenia and
frequent infection.
Other treatment options include hydroxychloroquine, parenteral
gold, corticosteroids, IV immunoglobulins, and plasmapheresis
(Woolston & Connelly, 2017).
Splenectomy may be considered as a last resort in patients
unresponsive to these treatments (Owlia et al., 2014).
Principal treatment includes antirheumatic drug therapy, along with
efforts to reduce susceptibility to infection such as (1) general
strategies such as good dental hygiene, good hand hygiene and
appropriate immunization (2) local treatment of skin ulceration
along with PT to avoid prolonged immobility, and (3) specialist
consultation as indicated (Kay, 2017).

Take home point: It is important to remember that the

diagnosis of FS may be masked in patients who present with
infection, since active bacterial infection raises the WBC count to
normal or slightly elevated – the neutropenia reappears shortly
after successful treatment (Kay, 2017).
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